In patients with chronic obstructive pulmonary disease (COPD) who experience further
exacerbations or symptoms, despite being prescribed dual long-acting muscarinic …

Background Single inhaler triple therapies providing an inhaled corticosteroid, a long-acting
muscarinic antagonist, and a long-acting β 2-agonist (ICS/LAMA/LABAs) are an emerging …

Triple therapy in COPD: only for the right patient | European Respiratory Society Skip to main
content Main menu Home Current issue ERJ Early View Past issues ERS Guidelines …

Abstract Background Randomised control trials (RCTs) with strict eligibility criteria can lead
to trial populations not commonly seen in clinical practice. We described the proportion of …

Background Triple therapy combinations of a long-acting muscarinic antagonist (LAMA), a
long-acting beta 2-agonist (LABA), and an inhaled corticosteroid (ICS) for COPD were …

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality
worldwide. Indications for the use of long-acting β2-agonists (LABAs) and inhaled …

Background This study assessed patient-level characteristics and patterns of medication use
in patients with chronic obstructive pulmonary disease (COPD) before initiation of multiple …

Background Real-world prescription pathways leading to triple therapy (TT)(inhaled
corticosteroid [ICS] plus long-acting β2-agonist bronchodilator [LABA] plus long-acting …

Background Limited data are available for the efficacy of triple therapy with two long-acting
bronchodilators and an inhaled corticosteroid in chronic obstructive pulmonary disease …

This is the protocol for a review and there is no abstract. The objectives are as follows: To
assess the efficacy and safety of treatment options for patients whose chronic obstructive …